carboplatin + paclitaxel + lenvatinib + pembrolizumab

carboplatin + paclitaxel + lenvatinib + pembrolizumab is a four-drug combination therapy utilized in oncology. Each constituent has a distinct mechanism of action and contributes synergistically to antitumor activity: - **Carboplatin** is a platinum-based chemotherapy agent that causes DNA cross-linking and cell death, primarily used in solid tumors[1][2][3][4][5][6][7]. - **Paclitaxel** is a taxane class chemotherapy that stabilizes microtubules and inhibits cell division[1][2][3][4][5][6][7]. - **Lenvatinib** is a small molecule inhibitor targeting multiple tyrosine kinases including VEGFR, FGFR, PDGFR, KIT, and RET, resulting in inhibition of angiogenesis and tumor growth. - **Pembrolizumab** is a monoclonal antibody acting as a programmed death 1 (PD-1) checkpoint inhibitor that promotes an immune response against cancer cells. The combination is investigated and used in advanced solid tumors, particularly endometrial cancer and other malignancies where multi-modality therapy is considered to increase efficacy. This regimen is under clinical investigation for synergistic effects in immune-oncology, anti-angiogenic, and cytotoxic mechanisms.